| 5.5 -0.666 (-10.8%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.84 | 1-year : | 6.82 |
| Resists | First : | 5 | Second : | 5.84 |
| Pivot price | 3.78 |
|||
| Supports | First : | 2.52 | Second : | 1 |
| MAs | MA(5) : | 3.55 |
MA(20) : | 3.47  |
| MA(100) : | 6.05 |
MA(250) : | 2.98 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 51.6 |
D(3) : | 65.6 |
| RSI | RSI(14): 39 |
|||
| 52-week | High : | 10.62 | Low : | 0.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GRAY ] has closed above bottom band by 16.5%. Bollinger Bands are 69.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.56 - 3.57 | 3.57 - 3.59 |
| Low: | 3.34 - 3.36 | 3.36 - 3.39 |
| Close: | 3.35 - 3.39 | 3.39 - 3.42 |
Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.
Fri, 05 Apr 2024
Graybug Vision (NASDAQ:GRAY) Stock Price Up 3.9% - Defense World
Fri, 05 Apr 2024
Graybug Vision (NASDAQ:GRAY) Trading Up 3.9% - Defense World
Mon, 20 Mar 2023
CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement - GlobeNewswire
Mon, 21 Nov 2022
Graybug and CalciMedica Enter into Definitive Merger Agreement - GlobeNewswire
Fri, 15 Apr 2022
Galecto Inc (NASDAQ: GLTO) Enrolls Patients in GULLIVER-2 Study - BP Journal
Fri, 15 Apr 2022
Graybug Vision Inc (NASDAQ: GRAY) Gives an Update on its Lead Drug Candidates - BP Journal
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 22 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 54.5 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 40 (K) |
| EPS | -20.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.65 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -38.2 % |
| Return on Equity (ttm) | -70.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -14 (M) |
| PE Ratio | -0.17 |
| PEG Ratio | 0 |
| Price to Book value | 2.04 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|